Breast Cancer Profiling Project, Drug Sensitivity phase I: Fixed-cell GR measures of 35 breast cell lines to 34 small molecule perturbagens from library plate I. Dataset 2 of 2: Calculated dose response metrics - Dataset (ID:20344)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Primary Target | Pathway | GR50 | GRmax | GR_AOC | Death_AUC | GR Hill Coefficient | GEC50 | GR r2 |
---|---|---|---|---|---|---|---|---|---|---|
CAMA-1 | Etoposide | Topo II | Chemotherapy | 0.15466 | -0.4476 | 0.5722 | 0.1479 | 1.3512 | 0.24426 | 0.99498 |
BT-549 | Dinaciclib | pan CDK | Cell cycle | 0.012371 | -0.2923 | 0.5913 | 0.1485 | 3.7837 | 0.013904 | 0.99899 |
MCF7 | Ceritinib | ALK | RTK | 0.34376 | -0.6157 | 0.4566 | 0.1487 | 0.9502 | 0.88109 | 0.9932 |
MDA-MB-134-VI | AZD7762 | CHK1/2 | Cell cycle | 0.10625 | -0.6459 | 0.6552 | 0.1488 | 1.1125 | 0.22232 | 0.99438 |
BT-549 | Volasertib | PLK | Cell cycle | 0.0088352 | -0.2289 | 0.5676 | 0.1490 | 2.4967 | 0.0098732 | 0.99586 |
MCF 10A | Tivantinib | MET | RTK | 0.18116 | -0.1502 | 0.4509 | 0.1498 | 2.3782 | 0.1918 | 0.99221 |
BT-549 | Bleomycin | Radiation | Misc | 0.17998 | -0.0141 | 0.4667 | 0.1506 | 1.0031 | 0.20287 | 0.99525 |
PDX1328 | Topotecan | Topo I | Chemotherapy | 0.0059222 | -0.9128 | 1.0720 | 0.1509 | 0.4616 | 0.063175 | 0.94441 |
MDA-MB-468 | Neratinib | EGFR/HER2 | RTK | 0.15781 | -0.3825 | 0.3861 | 0.1513 | 0.8303 | 0.41607 | 0.99579 |
HCC70 | Tivantinib | MET | RTK | 0.3335 | -0.5657 | 0.4968 | 0.1515 | 2.0000 | 0.48673 | 0.99617 |
Hs 578T | Buparlisib | pan PI3K | PI3K/mTOR | 0.68631 | -0.3434 | 0.3760 | 0.1520 | 1.4596 | 1.0562 | 0.9918 |
MDA-MB-134-VI | Dinaciclib | pan CDK | Cell cycle | 0.010529 | -0.8440 | 0.7452 | 0.1522 | 2.1701 | 0.015963 | 0.99365 |
PDXHCI002 | Luminespib | HSP90 | Misc | 0.0043954 | -0.2805 | 0.7099 | 0.1525 | 3.6850 | 0.0049332 | 0.9976 |
MDA-MB-453 | Abemaciclib | CDK4/6 | Cell cycle | 0.0057723 | -0.7647 | 0.8495 | 0.1526 | 0.2725 | 0.32512 | 0.73985 |
MDA-MB-436 | Taxol | Chemo | Chemotherapy | 0.0037097 | -0.2183 | 0.7083 | 0.1530 | 3.2043 | 0.0040962 | 0.99739 |
SK-BR-3 | Vorinostat | HDAC | Misc | 0.7625 | -0.6322 | 0.3637 | 0.1534 | 2.3291 | 1.0657 | 0.99404 |
SUM149PT | Cisplatin | Chemo | Chemotherapy | 0.57047 | -0.2290 | 0.3547 | 0.1535 | 0.9378 | 0.98129 | 0.99267 |
PDX1328 | ABT-737 | Bcl2/XL | Misc | 1.0279 | -0.8967 | 0.3548 | 0.1542 | 1.3255 | 2.3546 | 0.97784 |
HCC1395 | Doxorubicin | Chemo | Chemotherapy | 0.01793 | -0.4166 | 0.6370 | 0.1543 | 1.1158 | 0.025315 | 0.96347 |
HCC70 | Taselisib | PI3Ka, g, d | PI3K/mTOR | 0.15092 | -0.6846 | 0.5796 | 0.1546 | 0.7043 | 0.64661 | 0.98584 |
HCC1395 | Dinaciclib | pan CDK | Cell cycle | 0.012405 | -0.4966 | 0.6520 | 0.1554 | 2.9854 | 0.015612 | 0.99791 |
MDA-MB-468 | Luminespib | HSP90 | Misc | 0.0048347 | -0.1738 | 0.6478 | 0.1563 | 4.7025 | 0.0051177 | 0.99878 |
CAL-120 | Tivantinib | MET | RTK | 0.25132 | -0.2562 | 0.4649 | 0.1572 | 1.1267 | 0.37355 | 0.99876 |
MDA-MB-453 | Ceritinib | ALK | RTK | 0.36617 | -0.6866 | 0.4840 | 0.1577 | 1.1705 | 0.84209 | 0.99139 |
HCC1419 | Luminespib | HSP90 | Misc | 0.0069643 | -0.2968 | 0.6506 | 0.1579 | 2.0439 | 0.0087353 | 0.99699 |